Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

FDA Approves Launch of Generic Version of Xyzal

By Pharmaceutical Processing | November 29, 2010

Perrigo today announced that its licensor and supplier Synthon
has received final approval from the FDA for Levocetirizine tablets, a generic
version of Xyzal tablets from UCB/Sepracor, which is marketed in the U.S. by Sanofi-Aventis.
Perrigo has the exclusive rights from Synthon to sell and distribute the
product in the U.S.
The Synthon product is the only approved generic product having a label
containing all indications as the brand product and is entitled to 180 days of
exclusivity for a product labeled for both allergy and hives. Product shipments
commenced immediately upon FDA approval.

Levocetirizine tablets (Xyzal) are indicated for the
treatment of indoor and outdoor allergies. According to Wolters Kluwer Health, sales
for Xyzal Tablets for the 12 month period ending September 2010, were $224
million, a 12% increase over the previous 12 month period.

Perrigo’s
Chairman and CEO Joseph C. Papa stated, “This is a terrific example of
Perrigo leveraging its strong partnerships in bringing new products to market.
We are excited to see the continued expansion of our generic Rx portfolio of
products.” Synthon’s CEO Rudy Mareel commented, “Levocetirizine is
one of several ANDAs for which Synthon has obtained ‘First-Filer’-status with
180 days Hatch-Waxman marketing exclusivity. We are proud of this achievement
and of our cooperation with Perrigo.”

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE